RxDoctor Payments Data

Talha Awwal, MD

Internal Medicine · Carlsbad, NMNPI 1386123701

Payments from drug & device makers

$293in general payments, 2019–2025

Across 16 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$61
  • Abbott$47
  • Incyte Corporation$35
  • Axonics, Inc.$28
  • Lilly USA, LLC$22
  • Epizyme, Inc.$18
  • plus $82 from 5 others

What the payments were for

  • Food & beverage$293100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$293 in reported general payments places this provider in the 70th percentile of 578 internal medicine providers in New Mexico.

See all internal medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$269,661
Medicare patients
494
Services billed
15,475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide71$82,586
OzempicSemaglutide40$69,800
EliquisApixaban79$58,385
JardianceEmpagliflozin40$40,958
MounjaroTirzepatide18$28,867
MyrbetriqMirabegron33$24,267
Repatha SureclickEvolocumab26$21,539
XareltoRivaroxaban19$21,024
FarxigaDapagliflozin Propanediol13$18,585
JanuviaSitagliptin Phosphate20$17,837
Breo ElliptaFluticasone/Vilanterol24$9,626
Spiriva HandihalerTiotropium Bromide16$8,885
Praluent PenAlirocumab12$7,033
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$6,764
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$6,650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$22$111,45389 claims
Astellas Pharma US IncMyrbetriq$17$24,26733 claims
MerckJanuvia$17$17,83720 claims
AbbVieSynthroid$14$2,02654 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 578 internal medicine providers in New Mexico.

Other internal medicine in Carlsbad

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →